Lp(a). X CV risk

 Here are 3 key points from the passage:

1. Higher Lp(a) threshold (≥175 nmol/L) is a stronger predictor of cardiovascular risk.
New evidence from randomized trials shows that lipoprotein(a) levels ≥175 nmol/L—higher than the commonly used ≥125 nmol/L—are independently associated with increased risk of death, cardiovascular death, and stroke, with risk levels approaching those of smoking.

2. Risk increases progressively, especially beyond 125 nmol/L.
While current guidelines (like those from the American College of Cardiology and American Heart Association) consider ≥125 nmol/L a risk-enhancing level, this study shows a sharper rise in major adverse cardiovascular events (MACE) starting above 125 nmol/L and peaking at ≥175 nmol/L.

3. Implications for screening and future treatment strategies.
Although no approved therapies specifically target Lp(a) yet, the findings support routine measurement and may shift treatment thresholds. Ongoing trials like OCEAN(a) trial are testing targeted therapies, which could change how high-risk patients are managed in the future.

If you want, I can condense these into ultra-short exam bullet points.